The status of KRAS mutations in patients with non-small cell lung cancers from mainland China
KRAS mutation is closely associated to carcinogenesis and prognosis of non-small cell lung cancer (NSCLC). Detection of KRAS mutation can also be used to select NSCLC patients for drug targeting with EGFR tyrosine kinase inhibitors. Data regarding the status of KRAS mutation in mainland China, which would assist in these interventions, is lacking. We have detected KRAS mutation from 103 NSCLC patients in mainland China with high resolution melting analysis (HRM) on LightScanner™, and compared...[Show more]
|Collections||ANU Research Publications|
|01_Li_The_status_of_KRAS_mutations_2009.pdf||421.89 kB||Adobe PDF||Request a copy|
Items in Open Research are protected by copyright, with all rights reserved, unless otherwise indicated.